Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based Teva Pharmaceutical Industries has announced that the FDA has granted final approval to market its generic version of Novartis' antiepileptic therapy Trileptal tablets.
Subscribe to our email newsletter
The FDA has approved Teva’s abbreviated new drug application for oxcarbazepine tablets at 150mg, 300mg and 600mg milligrams. The drug is used to help control certain kinds of seizures and works by decreasing abnormal excitement in the brain.
Shipment of the product will begin in the near future. Teva is currently involved in patent litigation concerning this product in the US District Court for the district of New Jersey. A trial date has not been set.